Related Experiment Video
Updated: Sep 4, 2025
An In Vitro Bladder Model of Catheter-Associated Urinary Tract Infection
Published on: June 24, 2025
Effect of Urinary Trypsin Inhibitor (Ulinastatin) Therapy in COVID-19
Ashish Jain1, Rajeev Kasliwal2, Srishti Suresh Jain3
1Respiratory Medicine, Mahatma Gandhi Medical College and Hospital, Jaipur, Rajasthan, India.
Insights
Ulinastatin therapy did not significantly alter intensive care unit (ICU) length of stay or in-hospital mortality for COVID-19 patients. Further research with larger sample sizes is needed to confirm these findings for ulinastatin in COVID-19 treatment.
Area of Science:
- Critical care medicine
- Infectious diseases
- Pharmacology
Background:
- Coronavirus disease-2019 (COVID-19) can cause severe end-organ damage due to a "cytokine storm."
- Ulinastatin, a urinary trypsin inhibitor, has been explored as a novel therapy for COVID-19.
- Understanding the efficacy of ulinastatin is crucial for managing severe COVID-19 cases.
Purpose of the Study:
- To investigate the therapeutic efficacy of ulinastatin in patients with COVID-19.
- To compare outcomes such as ICU length of stay and mortality between patients receiving ulinastatin and a control group.
Main Methods:
- Retrospective analysis of medical records from COVID-19 patients.
- Propensity score matching was used to create comparable treatment and control groups.
- Statistical analysis and survival curve plotting were employed to assess outcomes.
Main Results:
- After propensity score matching, 55 patients were analyzed.
- No statistically significant differences were observed in ICU length of stay (p=0.28) or in-hospital mortality (OR=0.491, p=0.435) between the ulinastatin and control groups.
- Survival analysis also showed no significant difference between the groups (p=0.414).
Conclusions:
- Ulinastatin therapy did not demonstrate a significant impact on ICU length of stay or in-hospital mortality in this retrospective study of COVID-19 patients.
- The findings suggest that ulinastatin may not be effective in mitigating the severe outcomes associated with COVID-19.
- Larger, adequately powered randomized controlled trials are necessary to definitively establish the role of ulinastatin in COVID-19 treatment.
Purpose:
End-organ damage in coronavirus disease-2019 (COVID-19) is linked to "cytokine storm" and excessive release of inflammatory mediators. Various novel therapies have been used in COVID-19 including urinary trypsin inhibitor therapy. This study explores the efficacy of ulinastatin in COVID-19.
Materials And Methods:
We retrieved the medical records of patients admitted during one month and did a propensity score analysis to create matched treatment and control groups. We analyzed these groups and the outcomes were presented with appropriate statistics. Survival curve was prepared to compare the survival effect of ulinastatin therapy at the end of hospitalization, among both the groups.
Results:
A total of 736 patients were admitted, and after adjusting the data with propensity score matching, 55 cases were selected by the system. On the final outcome analysis, we found that intensive care unit (ICU) length of stay [median (interquartile range) days 3 (3.5-7.8) vs 2 (0-4); p-value 0.28] in control vs intervention groups, and in hospital mortality (odds ratio: 0.491, CI 95%: 0.099-2.44, p-value 0.435) were not statistically different among the groups. In survival plot analysis also, there was no statistical difference (p-value 0.414) among both the groups.Conclusion: In this retrospective study, we conclude that the final outcome of the ICU length of stay, and overall, in hospital mortality were not different among both the groups. Hence, adequately powered randomized control trials are urgently required to confirm any benefit of ulinastatin therapy in COVID-19 treatment.
How To Cite This Article:
Jain A, Kasliwal R, Jain SS, Jain R, Gupta D, Gupta P, et al. Effect of Urinary Trypsin Inhibitor (Ulinastatin) Therapy in COVID-19. Indian J Crit Care Med 2022;26(6):696-703.
More Related Videos
10:23Urinary Tract Infection in a Small Animal Model: Transurethral Catheterization of Male and Female Mice
Published on: December 1, 2017
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Related Concept Videos
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
01:25Urinary Tract Infection II: Pathophysiology
01:17Urinary Tract Infection IV: Nursing Management
01:26Urinary Tract Infection I: Introduction
01:26Urine Studies II: Urine Culture and Sensitivity Test
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention